Hot Healthcare Equipment Companies To Buy For 2015

BALTIMORE (Stockpickr) -- Love is in the air on Wall Street this Valentine's Day -- just maybe not the way you think.

>>5 Stocks Set to Soar on Bullish Earnings

No, I'm not talking about hedge fund managers' personal lives. I'm talking about their portfolios.

Pro investors' favorite stocks are telling right now, especially given the big sentiment swings we've been seeing in the broad market for the last couple of months. So it's interesting to know that institutional investors went on a buying spree last quarter, picking up big stakes in new names, and adding onto old favorites. In particular, their buying points to a lot of conviction in the technology and industrials sectors.

But what's more interesting is the specific stocks they're buying. To figure that out, we've got to take a closer look at 13F filings.

>>5 Rocket Stocks to Buy for a Market Bounce

Institutional investors with more than $100 million in assets are required to file a 13F -- a form that breaks down their stock positions for public consumption. From hedge funds to mutual funds to insurance companies, any professional investors who manage more than that $100 million watermark are required to file a 13F.

Top 10 Undervalued Stocks To Own Right Now: ChemoCentryx Inc (CCXI)

ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company�� wholly owned subsidiary is ChemoCentryx Limited.

The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company�� Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK).

The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of th! e immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.

CCX354 targets the chemokine receptor known as CCR1. Synovial fluid from the joints of rheumatoid arthritis (RA) patients contains high levels of activated CCR1 chemokine ligands. The Company completed two Phase I clinical trials in a total of 84 healthy subjects, conducted in Switzerland followed by a Phase I/II clinical trial in 24 patients with stable RA, conducted in Belgium and Romania, and a Phase II proof-of-concept clinical trial in 160 patients with moderate-to-severe RA, conducted in Belgium, the Czech Republic, Germany, Hungary, Poland, Romania and the Ukraine. GSK exercised its option to further develop and commercialize CCX354 in November 2011 and had an exclusive right to initiate a Phase II b clinical trial for CCX354 in RA.

CCX168 targets the chemo-attractant C5a receptor (C5aR), which binds to a biologically activated fragment of the complement protein known as C5. As of December 31, the Company completed a Phase I clinical trial for CCX168, conducted in Switzerland. The Company initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011. Its CCX872 is an independent next generation CCR2 drug candidate for the treatment of metabolic diseases, its CCX507 is an independent drug candidate for the treatment of inflammatory bowel disease (IBD) and CCX662 is an independent drug candidate for the treatment of glioblastoma multiforme (GBM).

The Company competes with Abbott Laboratories, Amgen Inc, AstraZeneca plc, Biogen Idec Inc, Bayer AG, Elan Corporation plc, Glaxo Group Limited, Merck & Co Inc, Merck Serono, Takeda Pharmaceutical Co Ltd, Novartis AG! , Pfizer ! Inc, Reata Pharmaceuticals, Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb, Incyte Corp and UCB Pharma.

Advisors' Opinion:

• [By CRWE]

  ChemoCentryx, Inc. (Nasdaq:CCXI), reported that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 7, 2012, at 9:30 a.m. Eastern Time at the Millennium Broadway Hotel & Conference Center in New York, NY.

• [By James E. Brumley]

  The last few weeks haven't been particularly encouraging for Crohn's disease sufferers. In August, GlaxoSmithKline (NYSE: GSK) and ChemoCentryx (NASDAQ:CCXI) reported that a jointly-developed Crohn's drug, vercirnon, had failed to meet its late-stage trial endpoints. Though the in-development drug isn't dead in the water (GSK and CCXI could rework the drug, the testing regimen, or use it for other indications), it doesn't look good. Then this month - just a few days ago - Coronado Biosciences Inc. (NASDAQ:CNDO) reported that its Phase 3 trials of Crohn's disease drug TSO had also failed to meet its primary endpoints as well. Like vercirnon, CNDO isn't completely out of luck here with the treatment, but forging ahead with further development of the treatment is grasping at straws. Crohn's sufferers don't need to give up home just yet, however - TNI Biotech Inc. (OTCMKTS:TNIB) appears to have a Crohn's treatment that works, and should be able to sidestep the problems that plagued ChemoCentryx, GlaxoSmithKline, and Coronado Biosciences.

Hot Healthcare Equipment Companies To Buy For 2015: Bunge Limited(BG)

Bunge Limited, through its subsidiaries, engages in the agriculture and food businesses worldwide. Its Agribusiness segment is involved in purchasing, storing, transporting, processing, and selling agricultural commodities and commodity products, such as oilseeds and grains, primarily comprising soybeans, rapeseed or canola, sunflower seed, wheat, and corn. This segment serves animal feed manufacturers, wheat and corn millers, third party edible oil processing companies, and other oilseed processors, as well as livestock, poultry, and aquaculture producers. The company?s Sugar and Bioenergy segment produces and sells sugar and ethanol; generates electricity from burning sugarcane bagasse; and trades and merchandises sugar. As of December 31, 2011, this segment had a total installed capacity of approximately 144 megawatts; and sugarcane plantations of approximately 183,000 hectares under cultivation. Its Edible Oil Products segment offers packaged vegetable, including pack aged and bulk oils, shortenings, margarines, mayonnaise, and other products to baked goods companies, snack food producers, restaurant chains, foodservice distributors, and other food manufacturers. The company?s Milling Products segment produces and sells various wheat flours and bakery mixes; corn-based products; corn milling products primarily comprising dry milled corn meals, flours, and grits, as well as soy-fortified corn meal and corn-soy blend; and packaged milled rice. This segment serves industrial, bakery, and foodservice companies; and companies in food processing sector. Its Fertilizer segment produces, blends, and distributes nitrogen, phosphate, and potash formulations used for the cultivation of soybeans, corn, sugarcane, cotton, wheat, and coffee. This segment also produces single super phosphate; and ammonia, urea, and liquid fertilizers for the agriculture industry. Bunge Limited was founded in 1818 and is headquartered in White Plains, New York.

Advisors' Opinion:

• [By Maxx Chatsko]

  Investors will be on the lookout for further, perhaps larger, customer announcements in the coming quarters. Just remember that there is plenty of time between now and mid-2015. Until then, there should be no worries from the guidance and commercialization aid Solazyme will receive from agri-giants Bunge (NYSE: BG  ) and Archer Daniels Midland (NYSE: ADM  ) .

• [By Rich Smith]

  Bunge (NYSE: BG  ) has named�Todd Bastean, currently CFO of its North American division, to lead the division when Bunge North America CEO Soren Schroder takes over the whole company as CEO of Bunge Limited on June 1.

Hot Healthcare Equipment Companies To Buy For 2015: Shanda Games Ltd (GAME)

Shanda Games Limited (Shanda Games), incorporated on June 12, 2008, is engaged in the development and operation of online games and related businesses in the People�� Republic of China. Some of its online games are also Web games, which the Company categorizes as either massively multiplayer online role-playing games (MMORPGs) or advanced casual games, rather than as a separate category of online games. As of February 29, 2012, Shanda Games operated 35 online games. Its game player base, which consisted of 20.4 million average monthly active users and 4.5 million average monthly paying users for the three-month period ended December 31, 2011. In April 2011, the Company acquired a 51.85% interest in a game operating company, which provides services in East Asia.

As of December 31, 2011, the Company owned 149 software copyrights. As of December 31, 2011, it owned or licensed 53 trademarks. As of December 31, 2011, it owned or licensed 329 registered domain names, including its official Website and domain names registered in connection with each of the games the Company offers. As of December 31, 2011, it had 17 patent applications pending with the State Intellectual Property Office of China. The Company operates MMORPGs, advanced casual games and Web games in China. Its MMORPGs are action adventure-based and draw upon themes, such as martial arts adventure, fantasy, strategy and historical events. The Company develops and sources an array of game content through multiple channels, including in-house development, licensing, investment and acquisition, and joint operation. Through these channels, it has built a diversified game portfolio and a game pipeline.

The Company licenses games from international and domestic developers. As of February 29, 2012, 13 of its 35 online games were licensed from third-party developers, including Mir II. It invests in independent game development and operating studios identified by 18 Capital. The Company acquire intellectual property rights t! o online games; equity rights in online game development and operating studios, or an option to acquire equity interests in online game development and operating studios in the future.

The Company operates its business in People's Republic of China, through its wholly owned subsidiaries, which consist of Shengqu Information Technology (Shanghai) Co., Ltd. (Shengqu), Shengji Information Technology (Shanghai) Co., Ltd. (Shengji), Lansha Information Technology (Shanghai) Co., Ltd. (Lansha) and Kuyin Software (Shanghai) Co., Ltd (Kuyin); its variable interest entities and their subsidiaries (VIEs), which consist of Shanghai Hongli Digital Technology Co., Ltd. (Shanghai Hongli) and Shanghai Shulong Technology Development Co., Ltd. (Shanghai Shulong) and their wholly owned subsidiaries, Shanghai Shulong Computer Technology Co., Ltd. (Shulong Computer), Nanjing Shulong Computer Technology Co., Ltd. (Nanjing Shulong), Chengdu Youji Technology Co., Ltd. (Chengdu Youji), Tianjin Youji Technology Co., Ltd. (Tianjin Youji), Chengdu Aurora Technology Development Co., Ltd. (Chengdu Aurora), and Chengdu Simo Technology Co., Ltd. (Chengdu Simo).

The Company competes with Tencent Holdings Limited, NetEase.com, Changyou.com Limited, Perfect World Co., Ltd., Giant Interactive, Kingsoft Corporation Limited, KongZhong Corporation, NetDragon Websoft Inc., Nineyou International Limited, The9 Limited, Activision Blizzard, Inc., Electronic Arts Inc., Zynga Inc., NCSoft Corporation, and Nexon Corporation.

Advisors' Opinion:

• [By Eric Volkman]

  Shanda Games� (NASDAQ: GAME  ) saw a decline in bottom line for its Q3, but still beat analyst estimates. The China-based company posted revenue of 1.12 billion yuan�($183 million), modestly higher than the 1.09 billion yuan�($178 million)�in the same period the previous year. Attributable net income came in at just under 399 million yuan ($65 million;�$0.24 per diluted American depositary share), compared with Q3 2012's 405 million yuan ($66 million;�$0.24).

Hot Healthcare Equipment Companies To Buy For 2015: Boulder Brands Inc (BDBD)

Boulder Brands, Inc., incorporated on May 31, 2005, is a supplier of gluten-free and health and wellness products in the United States and Canada. The Company distributes its products in all retail channels, including natural, grocery, club and mass merchandise. The Company also has a presence in the foodservice and industrial channels. The Company�� product portfolio consists of spreads, milk and other grocery products marketed under the Smart Balance, Earth Balance and Bestlife brands, and gluten-free products sold under the Udi's, Glutino and Gluten-Free Pantry brands. The Company operates in two segments: Smart Balance and Natural. The Smart Balance segment consists of its branded products in spreads, butter, grocery and milk. The Natural segment consists of its Earth Balance, Glutino and Udi's branded products. In December 2013, the Company announced that it has acquired 100% interests of Phil's Fresh Foods, LLC, owner of EVOL Foods (EVOL).

Smart Balance Products

The Smart Balance line of products is available in a range of categories, formats and sizes in the supermarket, mass merchandise and convenience store channels of distribution. Some of the Company�� buttery spreads are also available in bulk and individual serving formats for use in the industrial and foodservice channels. The Company�� Smart Balance buttery spreads are made from a patented blend of natural oils to help balance fats in the consumer's diet and to help improve the good-to-bad cholesterol ratio when used as part of the Smart Balance Food Plan. Smart Balance Spreadable Butters, available in original, light and extra virgin olive oil varieties, are a blend of creamery fresh butter and canola oil that contain less saturated fat than butter, as well as functional ingredients like EPA/DHA Omega-3 and plant sterols.

The Company offers a range of enhanced milk products, with different varieties containing EPA/DHA Omega-3s, plant sterols, and added levels of calcium and protein. The Comp! any use low and fat-free milks enhanced with non-fat milk solids to give the taste and texture of whole or reduced fat milk. The Company�� milk varieties include fat-free milk, 1% lowfat milk and lactose-free milk and are available in markets across the United States. The Company�� peanut butter products contain ALA Omega-3 from flax oil. The Company�� cooking oil and cooking sprays are designed for use in cooking, baking and salads to aid in avoiding trans fat and hydrogenated oils. The Company also markets a Smart Balance Buttery Burst Spray. The spray has zero calories, zero carbs and zero fats per serving and can be used as a pan spray or as a topping.

The Company�� Smart Balance Light Mayonnaise Dressing has half the fat of regular mayonnaise, is non-hydrogenated, contains zero grams of trans fat and contains natural plant sterols and ALA Omega-3. The Company created the Smart Balance Food Plan, incorporating many of its Smart Balance products, in order to help consumers achieve a healthy balance of natural fats in their daily diet. The plan includes menus, as well as numerous recipes.

Natural

The Earth Balance line of products offers a range of buttery spreads, sticks, soymilks, nut butters and vegan mayo dressings formulated for consumers interested in natural, plant based and organic products. Glutino offers a range of shelf stable and frozen gluten-free products, including snack foods, frozen baked goods, frozen entrees and baking mixes, throughout the United States and Canada. Glutino also offers a range of fresh breads under the Genius brand name. Based in Denver, Colorado, Udi's markets gluten-free products under the Udi's Gluten Free Foods brand in the retail market. The Company owns and operates a health and wellness, subscripton-based Website at www.thebestlife.com, which is based on the philosophies of Bob Greene.

The Company competes with Unilever, ConAgra Foods, Dean Foods, Land O' Lakes, Hain Celestial Group, Inc., Food for L! ife, Van'! s, Nature's Path, Mary's Gone Crackers, Enjoy Life, Pamela's Gluten Free, Rudi's Gluten-Free, French Meadow Bakery, Schar, Kinnikinnick, Amy's Gluten Free, Snyder's, Blue Diamond Gluten-Free, Bob's Red Mill Gluten-Free and Food Should Taste Good.

Advisors' Opinion:

• [By Selena Maranjian]

  Boulder Brands (NASDAQ: BDBD  ) gained 38%, and though you may think you don't know the company, it used to be Smart Balance until recently, and sports healthy-leaning brands, such as Smart Balance, Udi's, Glutino, Earth Balance, and Best Life. (The company is based�in New Jersey, not Colorado, too.) Boulder recently bought 80% of GlucoBrands, owner of Level Life Foods, which specializes in blood-sugar-managing products such as bars and shakes. Boulder Brands is free-cash-flow positive�and enjoying double-digit�revenue growth.

• [By David Sterman]

  Although shares of Boulder Brands (Nasdaq: BDBD) are up more than 60% since then, Home Loan Servicing (Nasdaq: HLSS) has merely treaded water while Swift Energy has continued its downward ascent.

• [By John Udovich]

  However and not helping the stock around that time was a very�lengthy article by the�Prescience Point Research Group on Seeking Alpha entitled: Fleetmatics Group PLC: Accounting Shenanigans Are Inflating Its Financials, While Insiders Sell Aggressively. Investors and shorts alike can read the article and make their own judgment, but some of the commenters have pointed out that similar attack articles from Prescience Point Research Group on stocks like the Active Network Inc (NYSE: ACTV) and Boulder Brands Inc (NASDAQ: BDBD) have backfired on the shorts. With that said, the article does highlight some of the risks investors face with the stock.

• [By WWW.DAILYFINANCE.COM]

  sixflags.com Plenty of stocks go up and down in any given week. The gainers inspire us to keep investing. The decliners keep greed in check while reminding us about the risks of the equity markets. Let's go over some of last week's best and worst performers. Regulus Therapeutics (RGLS) -- Up 161 percent last week Last week's biggest winner was a biotech upstart that got welcome news on a potential hepatitis C treatment. Regulus Therapeutics is showing that patients receiving a single injection of its drug are reporting lower viral loads a month later. There are still plenty of regulatory hurdles to clear, but it's certainly encouraging. Select Comfort (SCSS) -- Up 21 percent last week Shares of Select Comfort moved higher after it announced blowout quarterly results. The company behind the Sleep Number air-chambered mattresses saw net sales and earnings per share climb 23 percent and 22 percent, respectively. Select Comfort's strong performance was fueled by an impressive 16 percent spike in comparable-store sales. The favorable momentum is going to linger: Select Comfort is boosting its guidance for the entire year. Six Flags (SIX) -- Up 16 percent last week It was a summer of thrills at Six Flags. Shares of the regional amusement park operator rose like a coaster on a chain lift after it announced better-than-expected revenue growth. Revenue increased 7 percent on a combination of a slight uptick in attendance, higher admission prices, and guests spending more once inside the park. The report was encouraging enough for Six Flags to boost its dividend. The stock is now yielding a hearty 5.3 percent. Boulder Brands (BDBD) -- Down 31 percent last week Shares of Boulder Brands lost nearly a third of their value after the food company behind Smart Balance buttery spreads and EVOL frozen entrees warned of a soft holiday quarter. It now foresees net sales of $132 million to $137 million for the fourth quarter. We would be looking at a sequential dip from